JOHN NEUMEYER

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors
    John L Neumeyer
    Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, Massachusetts 02478 9106, USA
    J Med Chem 55:3878-90. 2012
  2. pmc Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands
    Michael Decker
    Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, Massachusetts 02478 9106, USA
    J Med Chem 52:7389-96. 2009
  3. pmc New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores
    John L Neumeyer
    Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, Massachusetts 02478, USA
    J Med Chem 49:5640-3. 2006
  4. pmc Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors
    Xuemei Peng
    Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, Massachusetts 02478, USA
    J Med Chem 50:2254-8. 2007
  5. pmc Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors
    Brian S Fulton
    Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA
    Bioorg Med Chem Lett 20:1507-9. 2010
  6. pmc Synthesis and pharmacological evaluation of hydrophobic esters and ethers of butorphanol at opioid receptors
    Brian S Fulton
    Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA
    Bioorg Med Chem Lett 18:4474-6. 2008
  7. pmc High-affinity carbamate analogues of morphinan at opioid receptors
    Xuemei Peng
    Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA
    Bioorg Med Chem Lett 17:1508-11. 2007
  8. ncbi request reprint 10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed kappa and micro opioid ligands: synthesis and biological evaluation of their binding affinity at opioid receptors
    Ao Zhang
    Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, Massachusetts 02478, USA
    J Med Chem 47:165-74. 2004
  9. ncbi request reprint Receptor affinities of dopamine D1 receptor-selective novel phenylbenzazepines
    John L Neumeyer
    Department of Psychiatry and Neuroscience Program, Harvard Medical School, Boston, MA, USA
    Eur J Pharmacol 474:137-40. 2003
  10. ncbi request reprint Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors
    John L Neumeyer
    Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, Massachusetts 02478, USA
    J Med Chem 46:5162-70. 2003

Research Grants

Collaborators

Detail Information

Publications29

  1. pmc Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors
    John L Neumeyer
    Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, Massachusetts 02478 9106, USA
    J Med Chem 55:3878-90. 2012
    ..Most 3-benzylaminomorphinan derivatives were partial agonists at MOR and full agonists at KOR in the [(35)S]GTPĪ³S binding assay...
  2. pmc Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands
    Michael Decker
    Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, Massachusetts 02478 9106, USA
    J Med Chem 52:7389-96. 2009
    ..95 and 0.62 nM for the mu and kappa receptors, respectively. Both 4a and 4b were partial agonists at the kappa and micro receptors in the [(35)S]GTPgammaS binding assay...
  3. pmc New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores
    John L Neumeyer
    Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, Massachusetts 02478, USA
    J Med Chem 49:5640-3. 2006
    ..MCL 450 represents a useful starting point for the synthesis of other multiple opioid ligands endowed with analgesic properties with low tolerance and dependence...
  4. pmc Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors
    Xuemei Peng
    Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, Massachusetts 02478, USA
    J Med Chem 50:2254-8. 2007
    ..These ligands were evaluated in vitro by their binding affinity at mu, delta, and kappa opioid receptors and their relative efficacy in the [35S]GTPgammaS assay...
  5. pmc Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors
    Brian S Fulton
    Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA
    Bioorg Med Chem Lett 20:1507-9. 2010
    ..Two bivalent ligands with sub-nanomolar binding affinity at the mu and kappa opioid receptors were discovered...
  6. pmc Synthesis and pharmacological evaluation of hydrophobic esters and ethers of butorphanol at opioid receptors
    Brian S Fulton
    Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA
    Bioorg Med Chem Lett 18:4474-6. 2008
    ..The most potent (K(i)=61 pM at mu and 48 pM at kappa) novel agent was (-)-N-cyclobutylmethylmorphinan-3-yl-14-ol phenoxyacetate (4d)...
  7. pmc High-affinity carbamate analogues of morphinan at opioid receptors
    Xuemei Peng
    Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA
    Bioorg Med Chem Lett 17:1508-11. 2007
    ..At the mu receptor, compounds 1b, 1c, 2b, and 3b were agonists, while compounds 2c-e and 3c-e were mu agonists/antagonists...
  8. ncbi request reprint 10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed kappa and micro opioid ligands: synthesis and biological evaluation of their binding affinity at opioid receptors
    Ao Zhang
    Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, Massachusetts 02478, USA
    J Med Chem 47:165-74. 2004
    ..The high affinity of these carboxamido analogues, along with their greater lipophilicity and metabolic stability, make them promising candidates for further pharmacological investigation...
  9. ncbi request reprint Receptor affinities of dopamine D1 receptor-selective novel phenylbenzazepines
    John L Neumeyer
    Department of Psychiatry and Neuroscience Program, Harvard Medical School, Boston, MA, USA
    Eur J Pharmacol 474:137-40. 2003
    ..They require further functional testing to characterize their intrinsic activity, and for potential stimulant-antagonist actions, as observed with SKF-83959 and MCL-202...
  10. ncbi request reprint Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors
    John L Neumeyer
    Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, Massachusetts 02478, USA
    J Med Chem 46:5162-70. 2003
    ....
  11. ncbi request reprint Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors
    Xuemei Peng
    Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, Massachusetts 02478, USA
    J Med Chem 49:256-62. 2006
    ....
  12. pmc Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors
    Michael Decker
    Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, Massachusetts 02478 9106, USA
    J Med Chem 53:402-18. 2010
    ....
  13. pmc In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors
    Xuemei Peng
    Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, Belmont, MA 02478, USA
    Bioorg Med Chem 15:4106-12. 2007
    ..Functional activities of these compounds were measured in the [35S]GTPgammaS binding assay, illustrating that all of these ligands were kappa agonists. At the mu receptor, compounds 11 and 12 were mu agonist/antagonists...
  14. ncbi request reprint 2-aminothiazole-derived opioids. Bioisosteric replacement of phenols
    Ao Zhang
    Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA
    J Med Chem 47:1886-8. 2004
    ..This novel compound may be valuable for the development of long-acting analgesics and drug abuse medication...
  15. doi request reprint Synthesis and binding studies of 2-O- and 11-O-substituted N-alkylnoraporphines
    Yu Gui Si
    Alcohol Drug Abuse Research Center and Mailman Research Center, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA
    Bioorg Med Chem Lett 18:3971-3. 2008
    ..The most D(2)-potent (K(i)=97 nM) and selective novel agent (>100-fold vs. D(1) and 5-HT(1A) sites) was R(-)-2-(2-hydroxyethoxy)-11-hydroxy-N-n-propylnoraporphine (compound 11)...
  16. ncbi request reprint Kappa receptor bivalent ligands
    Xuemei Peng
    Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, Massachusetts 02478, USA
    Curr Top Med Chem 7:363-73. 2007
    ..Bivalent ligands were also developed that could act as probes of the receptor-oligomerzation and organization phenomena. A structurally unique kappa antagonist (JDTic) provides an additional tool to characterize kappa opioid receptor...
  17. ncbi request reprint An investigation of the N-demethylation of 3-deoxymorphine and the affinity of the alkylation products to mu, delta, and kappa receptors
    Csaba Csutoras
    Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA
    Bioorg Med Chem 12:2687-90. 2004
    ..The mu, delta, and kappa receptor binding affinity of a series of N-substituted 3-deoxynormorphines 6 and 7 and N-substituted 3-deoxydihydronormorphines 8-11 was also determined...
  18. doi request reprint Synthesis and dopamine receptor affinities of N-alkyl-11-hydroxy-2-methoxynoraporphines: N-alkyl substituents determine D1 versus D2 receptor selectivity
    Yu Gui Si
    Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, Massachusetts 02478 9106, USA
    J Med Chem 51:983-7. 2008
    ....
  19. doi request reprint Synthesis and neuropharmacological evaluation of esters of R(-)-N-alkyl-11-hydroxy-2-methoxynoraporphines
    Yu Gui Si
    Alcohol Drug Abuse Research Center and Mailman Research Center, McLean Hospital, Harvard Medical School, Belmont, MA 02478, USA
    Bioorg Med Chem Lett 19:51-3. 2009
    ..9nM) and selective novel agent (>529-fold vs D(1) sites) was R(-)-2-methoxy-11-acetyloxy-N-n-propylnoraporphine (compound 4b). At moderate doses, the compound proved to have prolonged behavioral locomotor activity...
  20. ncbi request reprint Synthesis and amine transporter affinities of novel phenyltropane derivatives as potential positron emission tomography (PET) imaging agents
    Xuemei Peng
    Medicinal Chemistry Laboratory, Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02478 9106, USA
    Bioorg Med Chem Lett 14:5635-9. 2004
    ..18, 0.24, and 0.30 nM, respectively). Tosylate esters 17 and 18, synthesized as precursors for [(18)F]-labeled, Positron Emission Tomography (PET) imaging agents, also showed high affinity for DAT...
  21. ncbi request reprint Pharmacological characterization of the effects of dopamine D(1) agonists on eye blinking in rats
    Rajeev I Desai
    Preclinical Pharmacology Laboratory, McLean Hospital Harvard Medical School, Belmont, Massachusetts 02478, USA
    Behav Pharmacol 18:745-54. 2007
    ..Further studies with novel D(1)-like partial agonists may be useful in the development of pharmacotherapies for cocaine abuse...
  22. ncbi request reprint R-(-)-N-alkyl-11-hydroxy-10-hydroxymethyl- and 10-methyl-aporphines as 5-HT1A receptor ligands
    Yu Gui Si
    Alcohol Drug Abuse Research Center, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA
    Bioorg Med Chem Lett 17:4128-30. 2007
    ..Tested compounds displayed moderate to high affinity to 5-HT(1A) receptors but low affinity to D(1) and D(2) receptors. The most potent novel 5-HT(1A) agent was R-(-)-N-methyl-10-hydroxymethyl-11-hydroxyaporphine...
  23. ncbi request reprint Microwave-promoted Pd-catalyzed cyanation of aryl triflates: a fast and versatile access to 3-cyano-3-desoxy-10-ketomorphinans
    Ao Zhang
    Medicinal Chemistry Program, Alcohol and Drug Abuse Research Center, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, Massachusetts 02478, USA
    Org Lett 5:201-3. 2003
    ..This method is highly efficient for the preparation of 3-cyano-3-desoxy-10-ketomorphinans. The reaction was generally completed in 15 min at 200 degrees C and produced products in greater than 86% yields...
  24. pmc Behavioral effects of the R-(+)- and S-(-)-enantiomers of the dopamine D(1)-like partial receptor agonist SKF 83959 in monkeys
    Rajeev I Desai
    McLean Hospital Harvard Medical School, Belmont, MA 02478, USA
    Eur J Pharmacol 558:98-106. 2007
    ..In addition, the inactivity of MCL 201, the S-(-)-enantiomer, suggests that the behavioral effects of SKF 83959 can be attributed primarily to the activity of its R-(+)-enantiomer...
  25. ncbi request reprint Synthesis and neuropharmacological evaluation of R(-)-N-alkyl-11-hydroxynoraporphines and their esters
    Csaba Csutoras
    Alcohol and Drug Abuse Research Center, McLean Division of Massachusetts General Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02478 9106, USA
    Bioorg Med Chem 12:3553-9. 2004
    ..The 11-hydroxyaporphines showed similar neuropharmacological properties to the corresponding 10,11-catecholaporphines. At moderate doses, their esters proved to have more prolonged behavioral actions and superior oral bioavailability...
  26. ncbi request reprint Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties
    Jennifer L Mathews
    Department of Pharmacology and Physiology, University of Rochester School of Medicine and Dentistry, NY 14642 8711, USA
    J Pharmacol Exp Ther 315:821-7. 2005
    ..MCL-145 also acted as a mu antagonist, as measured by the inhibition of morphine-induced antinociception...
  27. ncbi request reprint Synthesis and pharmacological evaluation of 6,7-indolo/thiazolo-morphinans--further SAR of levorphanol
    Ao Zhang
    BioOrganic and Medicinal Chemistry Laboratory, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
    J Med Chem 50:2747-51. 2007
    ....
  28. ncbi request reprint Advances in development of dopaminergic aporphinoids
    Ao Zhang
    Synthetic Organic and Medicinal Chemistry Laboratory, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
    J Med Chem 50:171-81. 2007
  29. ncbi request reprint Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders
    Ao Zhang
    BioOrganic and Medicinal Chemistry Laboratory, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China
    Chem Rev 107:274-302. 2007

Research Grants10

  1. Mixed Kappa/Mu Opioids: Synthesis and Evaluation
    JOHN NEUMEYER; Fiscal Year: 2003
    ..Neumeyer, Ph.D. Novel compound in vivo and in vitro evaluations will be conducted by Jean M. Bidlack, Ph.D., in the Department of Pharmacology and Physiology at the University of Rochester under, a consortium arrangement. ..
  2. DOPAMINE TRANSPORTER IMAGING WITH FLUORINE-18 PET
    JOHN NEUMEYER; Fiscal Year: 2003
    ..The lead compound in this series (presently BRL-308) will be evaluated by PET imaging and pharmacokinetics, in non-human primates. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE ..
  3. Mixed Kappa-Mu Opioids: Synthesis and Evaluation
    JOHN NEUMEYER; Fiscal Year: 2009
    ..Neumeyer, Ph.D., and the pharmacological evaluation component will be conducted at the University of Rochester under the direction of Jean M. Bidlack, Ph.D. ..